Knisely Jane M, Buyon Lucas E, Mandt Rebecca, Farkas Rebecca, Balasingam Shobana, Bok Karin, Buchholz Ursula J, D'Souza M Patricia, Gordon Jennifer L, King Deborah F L, Le Tung T, Leitner Wolfgang W, Seder Robert A, Togias Alkis, Tollefsen Stig, Vaughn David W, Wolfe Daniel N, Taylor Kimberly L, Fauci Anthony S
Office of the Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
NPJ Vaccines. 2023 Apr 12;8(1):53. doi: 10.1038/s41541-023-00654-6.
On November 7th and 8th, 2022, The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), The Coalition for Epidemic Preparedness Innovation (CEPI), The Bill & Melinda Gates Foundation (BMGF), The Biomedical Advanced Research and Development Authority (BARDA), and the Wellcome Trust hosted a virtual workshop entitled “Mucosal Vaccines for SARS-CoV-2: Scientific Gaps and Opportunities.” During the workshop, researchers and vaccine developers from around the world discussed the potential of mucosal vaccines to block SARS-CoV-2 transmission and reviewed the status of SARS-CoV-2 mucosal vaccine research. Here, we summarize key challenges and opportunities in basic, translational, and clinical research that were highlighted during the meeting. We also provide recommendations to advance the field and accelerate the development of mucosal vaccines for SARS-CoV-2.
2022年11月7日至8日，美国国立卫生研究院（NIH）下属的国立过敏与传染病研究所（NIAID）、流行病防范创新联盟（CEPI）、比尔及梅琳达·盖茨基金会（BMGF）、生物医学高级研究与发展管理局（BARDA）以及惠康基金会联合举办了一场名为“针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的黏膜疫苗：科学差距与机遇”的虚拟研讨会。在研讨会上，来自世界各地的研究人员和疫苗开发者讨论了黏膜疫苗阻断SARS-CoV-2传播的潜力，并回顾了SARS-CoV-2黏膜疫苗的研究现状。在此，我们总结了会议期间强调的基础研究、转化研究和临床研究中的关键挑战与机遇。我们还提出了推进该领域发展并加速SARS-CoV-2黏膜疫苗研发的建议。
